Correction: Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3

T Zhang; J Li; F Yin; B Lin; Z Wang; J Xu; H Wang; D Zuo; G Wang; Y Hua; Z Cai

doi:10.1038/s41388-019-0738-1

Correction: Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3

Oncogene. 2019 Jun;38(23):4655-4656. doi: 10.1038/s41388-019-0738-1.

Authors

T Zhang^{1

2}, J Li³, F Yin^{4

5}, B Lin⁵, Z Wang^{4

5}, J Xu⁶, H Wang⁵, D Zuo⁵, G Wang⁵, Y Hua^{7

8}, Z Cai^{9

10}

Affiliations

¹ Department of Orthopedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [email protected].
² Shanghai Bone Tumor Institution, Shanghai, China. [email protected].
³ Institute of Translational Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
⁴ Department of Orthopedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
⁵ Shanghai Bone Tumor Institution, Shanghai, China.
⁶ Department of Pharmacology, Institute of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
⁷ Department of Orthopedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [email protected].
⁸ Shanghai Bone Tumor Institution, Shanghai, China. [email protected].
⁹ Department of Orthopedics, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [email protected].
¹⁰ Shanghai Bone Tumor Institution, Shanghai, China. [email protected].

Abstract

Since the publication of this paper, the authors have noticed that the article contains an error in Figure 3e (TSN, 50 nM). As a result of the misfiling of the data, the incorrect image was inadvertently inserted in Figure 3e during figure preparation. The corrected image is shown in this correction.

Publication types

Published Erratum